Liraglutide vs Selank
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Selank
Selank is a synthetic peptide derived from the naturally occurring immunomodulatory peptide tuftsin. Developed in Russia for anxiety and cognitive enhancement.
Full details →Side-by-Side Comparison
| Aspect | Liraglutide | Selank |
|---|---|---|
| Mechanism | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. | Modulates the expression of brain-derived neurotrophic factor (BDNF) and affects serotonin and norepinephrine systems. Has immunomodulatory and anxiolytic properties. |
| Typical Dosage | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. | Intranasal administration: 250-500mcg 2-3 times daily. Subcutaneous: 250-500mcg daily. |
| Administration | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. | Most commonly administered intranasally for cognitive effects. Can also be injected subcutaneously. |
| Side Effects | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. | Generally well-tolerated. Some users report mild fatigue or nasal irritation with intranasal use. |
| Best For |